Gene expression profiling of Polycomb, Hox and Meis genes in patients with acute myeloid leukaemia

European Journal of Haematology
Lykke GrubachMette Ostergaard

Abstract

The Polycomb group (PcG) of genes is important for differentiation and cell-cycle regulation and is aberrantly expressed in several cancers. To analyse the role of deregulated PcG genes in acute myeloid leukaemia (AML), we determined by RQ-PCR the expression of the PcG genes BMI-1, MEL18, SCML2, YY1 and EZH2, and the downstream PcG targets HOXA4, HOXA9 and MEIS1 in diagnostic bone marrow samples from 126 AML patients. There was a general overexpression of the genes in AML patients compared to 20 healthy donors, except of HOXA4 and MEL18, which both displayed a wide range of expression levels within the AML subgroups. Among the AML patients with normal karyotype, a low HOXA4 level was associated with a shorter overall survival (P = 0.005). In addition, expression levels of MEL18 and EZH2 were significantly (P < 0.025) higher in patients with complex karyotype and lower in CBF-mutated patients. The t(8;21) vs. inv(16) positive patients showed significantly different expression of SCML2, BMI-1, YY1, HOXA9 and MEIS1 (P < or = 0.01). Comparisons between the PcG and PcG-regulated genes and a number of clinical and molecular data revealed correlations to genes involved in DNA methylation (DNMT1, DNMT3B), apoptosis (BAX, CASPASE 3) and...Continue Reading

References

Dec 10, 1999·Proceedings of the National Academy of Sciences of the United States of America·R D HansonS J Korsmeyer
Dec 13, 2000·Molecular and Cellular Biology·U ThorsteinsdottirG Sauvageau
Aug 30, 2001·Proceedings of the National Academy of Sciences of the United States of America·Y YuanD E Zhang
Aug 9, 2002·Molecular and Cellular Biology·Stuart S LevineRobert E Kingston
Sep 23, 2003·Proceedings of the National Academy of Sciences of the United States of America·Celina G KleerArul M Chinnaiyan
Jan 24, 2004·Leukemia & Lymphoma·Sílvia CasasSakari Knuutila
Apr 1, 2004·Molecular Cell·Gaetano I DellinoVincenzo Pirrotta
Apr 16, 2004·The New England Journal of Medicine·Lars BullingerJonathan R Pollack
Apr 16, 2004·The New England Journal of Medicine·Peter J M ValkRuud Delwel
Aug 18, 2005·International Journal of Hematology·Masashi SawaTomoki Naoe
Nov 19, 2005·Blood·Leonie M KammingaGerald de Haan
Dec 7, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ingeborg M BachmannLars A Akslen
Dec 17, 2005·Nature·Emmanuelle ViréFrançois Fuks
Apr 19, 2006·Genes & Development·Adrian P BrackenKristian Helin
May 25, 2006·Heredity·T Svingen, K F Tonissen
Aug 18, 2006·Acta Haematologica·Elena SerranoJosep F Nomdedéu
Sep 13, 2006·British Journal of Haematology·Jorg BaseckeFred E Bertrand
Oct 25, 2006·Nature Reviews. Cancer·Anke Sparmann, Maarten van Lohuizen
Dec 13, 2006·Proceedings of the National Academy of Sciences of the United States of America·Frank H WilkinsonMichael L Atchison
Mar 10, 2007·The Journal of Clinical Investigation·Claudia SchollStefan Fröhling
May 8, 2007·Current Opinion in Cell Biology·Leonie Ringrose
Sep 6, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Gordon StrathdeeRobert Brown

❮ Previous
Next ❯

Citations

Aug 28, 2013·Cellular Oncology (Dordrecht)·Eigil Kjeldsen, Christopher Veigaard
Dec 14, 2011·Nature Reviews. Cancer·Mark P ChaoIrving L Weissman
Dec 21, 2010·American Journal of Respiratory and Critical Care Medicine·Xin LinJia Guo
Jul 8, 2008·BMC Evolutionary Biology·Hai-hui Wu, Bing Su
Mar 9, 2010·PloS One·Brady G Miller, John A Stamatoyannopoulos
Jan 18, 2012·Critical Reviews in Oncogenesis·Michael AtchisonMadhusudhan Papasani
Dec 18, 2013·The Journal of Clinical Investigation·Chinavenmeni S VeluH Leighton Grimes
Feb 1, 2014·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Apostolos ZaravinosDemetrios A Spandidos
Feb 8, 2011·Cancer Investigation·Yan-Wei LinJing-Yuan Fang
Jan 15, 2015·Molecular Medicine Reports·Ewa MusialikJanusz Aleksander Siedlecki
Nov 17, 2011·Biochemical and Biophysical Research Communications·Sungsin JoHeekyoung Chung
Jul 1, 2009·European Journal of Haematology·Mike ZangenbergPeter Hokland
Jan 27, 2011·Journal of Cellular Biochemistry·Akihide Yoshimi, Mineo Kurokawa
Dec 7, 2013·Developmental Dynamics : an Official Publication of the American Association of Anatomists·Nuala M MulgrewAlexander Thompson
Mar 24, 2016·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Qiuhua ZhuFanyi Meng
Jul 23, 2013·Developmental Dynamics : an Official Publication of the American Association of Anatomists·E LongobardiFrancesco Blasi
Jun 6, 2012·Hematology·Shigeaki UmedaMasanobu Kitagawa
Nov 12, 2009·Blood·Lars BullingerDirk van den Boom
Nov 25, 2011·Annals of Clinical Biochemistry·Ruth M Ayling
Nov 15, 2016·Oncogene·V TakiarL W T Cheung
Mar 28, 2013·Integrative Biology : Quantitative Biosciences From Nano to Macro·Ehsan Ghayoor Karimiani, Philip Day
Oct 8, 2013·Leukemia·K LundM Copland
Sep 30, 2017·Blood Cancer Journal·C K LaiR K Humphries
Oct 27, 2015·Oncotarget·Laurie HerviouJérôme Moreaux
Oct 30, 2016·Oncotarget·Anthos ChristofidesVassiliki A Boussiotis

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Cancer Epigenetics Chromatin Complexes (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on chromatin complexes and their role in cancer epigenetics.

Cancer Epigenetics and Chromatin (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on chromatin and its role in cancer epigenetics please follow this feed to learn more.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis